OptiBiotix Health PLC (GB:OPTI)
LSE:OPTI
Want to see GB:OPTI full AI Analyst Report?
OPTI Stock Chart & Stats
6.75 p
0.00 p(0.00%)
At close: 4:00 PM EST
6.75 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range4.50 p - 13.50 p
Previous CloseN/A
Volume20.25K
Average Volume (3M)268.80K
Market Cap
£6.46M
Enterprise Value5.42M
Total Cash (Recent Filing)£1.04M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta1.04
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding103,300,300
10 Day Avg. Volume266,472
30 Day Avg. Volume268,800
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.09
Price to Sales (P/S)5.86
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Recent Revenue GrowthA ~130% jump in 2025 revenue indicates accelerating commercial traction and partner adoption of its microbiome ingredients. Durable revenue expansion from licensing and ingredient supply can create a larger recurring royalty base and support scaling of fixed R&D and SG&A over coming quarters.
Improving Gross MarginsMargin improvement to ~53% reflects better unit economics and pricing or mix gains from higher-value partnerships. Sustained higher gross margins enhance the path to operating leverage as revenue grows, making future profitability more attainable if operating costs are controlled.
Conservative Leverage / Low DebtA largely debt-free balance sheet reduces refinancing and interest-rate risk and preserves flexibility for R&D, partnerships or selective M&A. This structural strength limits fixed financing obligations, lowering solvency risk while the business scales revenues and commercial milestones.
Bears Say
Persistent Negative Operating Cash FlowConsistent negative operating cash flow (~-£1.77m in 2025) signals ongoing cash burn to fund operations and commercialization. Over months, this structural cash gap raises reliance on external financing, increasing dilution or covenant risk unless the company achieves sustained positive cash generation.
Material And Widening Net LossesA ~£3.9m net loss that widened year-over-year indicates operating costs are scaling faster than revenue. Structurally, persistent losses limit internal reinvestment, pressure margins and require either meaningful margin expansion or sustained revenue growth to reach durable profitability.
Equity Erosion And Negative Returns On EquityDeclining equity and meaningfully negative ROE over multiple years reflect cumulative losses and shareholder value dilution. Over the medium term this undermines capital efficiency and heightens the risk that future financing comes at dilutive terms unless operating performance turns positive.
OptiBiotix Health News
OPTI FAQ
What was OptiBiotix Health PLC’s price range in the past 12 months?
OptiBiotix Health PLC lowest share price was 4.50 p and its highest was 13.50 p in the past 12 months.
What is OptiBiotix Health PLC’s market cap?
OptiBiotix Health PLC’s market cap is £6.46M.
When is OptiBiotix Health PLC’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were OptiBiotix Health PLC’s earnings last quarter?
Currently, no data Available
Is OptiBiotix Health PLC overvalued?
According to Wall Street analysts OptiBiotix Health PLC’s price is currently Overvalued.
Does OptiBiotix Health PLC pay dividends?
OptiBiotix Health PLC does not currently pay dividends.
What is OptiBiotix Health PLC’s EPS estimate?
OptiBiotix Health PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OptiBiotix Health PLC have?
OptiBiotix Health PLC has 103,300,300 shares outstanding.
What happened to OptiBiotix Health PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of OptiBiotix Health PLC?
Currently, no hedge funds are holding shares in GB:OPTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OptiBiotix Health PLC
OptiBiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; SlimBiome Medical, a natural supplement for weight management; CholBiome, a food supplement for maintaining healthy levels of cholesterol; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galactooligosaccharid that is used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; WellBiome, a functional fibre and mineral blend that supports health & wellbeing by promoting the diversity of the gut microbiome; and Sweetbiotix, a sweetener for use in food and beverages. The company's products prevents and manages chronic lifestyle diseases, including obesity, hypercholesterolemia and lipid profiles, and diabetes. OptiBiotix Health Plc was founded in 2012 and is headquartered in York, the United Kingdom.
Technical Analysis
Evgen Pharma
―
Futura Medical
―
Nuformix Plc
―
Cizzle Biotechnology Holdings PLC
―
SkinBioTherapeutics
―
Options Prices
Currently, No data available
---